TULEHDUKSELLISET PROSESSIT KROONISESSA BORRELIOOSISSA

[Bb]

Lähettäjä: Soijuv Lähetetty: 10.5.2004 8:57

Seuraavassa on lisää tietoa Marshallin hoitomenetelmästä, jota on jo jonkin aikaa käytetty sarkoidoosin hoidossa. Viesti on lääkäriltä joka tutkii borrelioosin patogeneesiä (sairastaa kroonista borrelioosia itsekin). Hän on tullut lyhyessä ajassa lähes oireettomaksi. Hoidoksi hän on käyttänyt Minosykliiniä 100 mg ja Benicaria 40 mg x 2. Hän kertoo olevansa 9 päivän käytön jälkeen 95 %:sesti terve. Benicaria käytetään tulehdusprosessin estämiseen eikä tässä tapauksessa verenpaineen hoitoon johon sitä alunperin markkinoidaan. Lääkettä tarvitaan suhteellisen korkea annos mutta sen ei ole viestin mukaan todettu aiheuttavan liian alhaista verenpainetta.


Greetings everyone,

My name is Scott Taylor. I am a DVM in Ames, Iowa and have had chronic borreliosis for 3 years.

I have concentrated my investigation on the pathogenesis of this disease in hopes of discovery a better therapeutic regimen. I have been fortunate to discover Dr. Trevor Marshall?s work with sarcoidosis. Dr. Marshall is the director of research at the Autoimmunity Research Foundation in Thousand Oaks, CA. His web site is: www.sarcinfo.com. I have been corresponding with Dr. Marshall for the past couple of weeks in regards to his work and borreliosis.

Briefly, Dr. Marshall has uncovered a major immunological Th1 inflammatory cascade that was unknown prior to this work: http://tinyurl.com/mcqa . It is my opinion, that this missing information explains much of our frustration in dealing with chronic borreliosis.

Dr. Marshall has discovered that angiotensin II type 1 receptor activation can perpetuate a Th1 inflammatory cascade as described above. I find this discovery extremely valuable and very applicable for therapeutic design, which Dr. Marshall has already investigated for sarcoidosis. Dr. Marshall has investigated the use of angiotensin receptor blockers to inhibit this perpetual inflammatory response. He found that the ARB, Benicar (olmesartan medoxomil) has the best AT1 receptor antagonistic properties for this purpose.

Please note that relatively high doses of Benicar are used to saturate the AT1 receptors found on macrophages and that this AT1 antagonism will stop the self-perpetuation inflammatory cascade. Also note that Dr. Marshall found that these high doses are tolerated extremely well and are very safe. The hypotensive properties of Benicar plateau, so the higher does do not cause hypotensive problems at the higher, anti-inflammatory doses, even in individual with prior hypotension.

I am one of two individuals with borreliosis in our country (probably in the world) that has used Benicar therapy for borreliosis. Others are beginning to use it now. Those of us that are using Benicar and Dr. Marshall?s protocol for sarcoidosis are having dramatic results.

I began taking Benicar (40 mg tid) along with minocycline (100 mg sid) 9 days ago at which time I was about 80-85% recovered after 1.5 years of therapy. With my first dose of Benicar (40 mg) I began noticing significant relief from all of my borreliosis symptoms. Now, after 9 days of Benicar and minocycline therapy, I?m dramatically better. I?d say almost 95% recovered. This experience has been miraculous for me and I believe it will for others suffering with this horrible disease.

I am requesting your help to make sure this great work by Dr. Marshall gets the recognition it deserves.

Please find attached some notes on the pathogenesis of borreliosis I?ve been keeping.

I look forward to corresponding with this group regarding this exciting information.

Sincerely,

Scott